An analysis of an Ontario claims database shows that a small proportion of neurologists prescribe most of the disease-modifying therapies (DMTs) for MS (Marriott et al. Can J Neurol Sci 2013;40:67-72). Overall, 80% of DMT prescriptions were written by 12% of the neurologist community.